Compare FuelCell Energy Inc (FCEL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs BIO-TECHNE Corp — how do they compare? FuelCell Energy Inc trades at $17.57 (market cap $1.47B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 7.7× FuelCell Energy Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and BIO-TECHNE Corp for 63 Days on average.
| FCEL | TECH | |
|---|---|---|
Market Cap | $1.47B | $11.37B |
Volume | 12,559,948 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $36.01 | $72.61 |
52-Week Low | $6.00 | $43.31 |
Typical Hold Time | 48 Days | 63 Days |
Enterprise Value | $1.05B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $17.245, down 16.49% over 24 hours, reflecting recent volatility amid a securities class action. The stock shows a bullish technical signal with support near $17 and resistance at $19. Fundamentally, the company reported revenue of $158.16 million for 2025 but posted a net loss of $187.90 million, with negative profit margins persisting. Cash flow improved in 2025 with net cash flow of $132.91 million, though operational cash flow remains negative.
The outlook is cautious; while analyst consensus suggests a $21.57 price target with 40% buy ratings, ongoing legal challenges and consistent losses pose significant risks. Investment opportunity hinges on execution turnaround and market adoption of hydrogen energy, but high volatility and financial instability warrant careful consideration.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
